Relay Therapeutics (RLAY) CEO sells 48K shares in plan trade

Rhea-AI Filing Summary

Relay Therapeutics, Inc. (RLAY) reported that President and CEO Sanjiv Patel sold 48,199 shares of common stock on August 17, 2026 in an open-market transaction at a weighted average price of $20.33 per share, effected pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025. Following this sale, he directly held 567,699 shares of common stock. Additional shares totaling 199,548 and 687,355 are held in separate irrevocable trusts for the benefit of his family members, with an independent trustee; Patel disclaims beneficial ownership of those trust-held securities.

Insider Trade Summary 10b5-1

Net Seller: 48,199 shares

Net Sell 3 txns

Insider Patel Sanjiv

Role President and CEO

Sold 48,199 shs ($980K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	48,199	$20.33	$980K
holding	Common Stock F3	--	--	--
holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 567,699 shares (Direct); Common Stock — 199,548 shares (Indirect, By The Patel Family Irrevocable Trust of 2019); Common Stock — 687,355 shares (Indirect, By The SSP Irrevocable Trust of 2020)

Footnotes (3)

1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $19.56 to $20.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Key Figures

Shares sold: 48,199 shares Weighted average sale price: $20.33 per share Sale price range: $19.56 to $20.73 per share +4 more

7 metrics

Shares sold 48,199 shares Common stock sale on August 17, 2026

Weighted average sale price $20.33 per share Open-market sale of common stock on August 17, 2026

Sale price range $19.56 to $20.73 per share Multiple trades comprising the August 17, 2026 sale

Direct holdings after sale 567,699 shares Directly held Relay Therapeutics common stock following the transaction

Patel Family Irrevocable Trust of 2019 holdings 199,548 shares Shares held in irrevocable trust for family members; beneficial ownership disclaimed

SSP Irrevocable Trust of 2020 holdings 687,355 shares Shares held in irrevocable trust for family members; beneficial ownership disclaimed

10b5-1 plan adoption date October 30, 2025 Date Sanjiv Patel adopted the Rule 10b5-1 trading plan governing this sale

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, irrevocable trusts, beneficial ownership

4 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

irrevocable trusts financial

"These shares are held in irrevocable trusts for the benefit of the reporting person's family members"

beneficial ownership financial

"The reporting person disclaims beneficial ownership of these securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

What insider transaction did RLAY CEO Sanjiv Patel report on this Form 4?

Sanjiv Patel reported a sale of 48,199 shares of Relay Therapeutics common stock on August 17, 2026 at a weighted average price of $20.33 per share, described as an open-market transaction.

Was the RLAY CEO’s August 17, 2026 stock sale under a 10b5-1 plan?

Yes. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan that Sanjiv Patel adopted on October 30, 2025, indicating the sale followed a pre-established trading arrangement.

How many RLAY shares does Sanjiv Patel hold directly after this reported sale?

After the reported transaction, Sanjiv Patel directly held 567,699 shares of Relay Therapeutics common stock, as reflected in the post-transaction holdings figure in the Form 4 data.

What price range did the RLAY CEO’s August 17, 2026 trades execute within?

The trades were executed in multiple transactions at prices ranging from $19.56 to $20.73 per share. The reported per-share figure of $20.33 represents the weighted average sale price across those trades.

What RLAY-related shares are held in trusts associated with Sanjiv Patel’s family?

The Form 4 reports 199,548 shares held by The Patel Family Irrevocable Trust of 2019 and 687,355 shares held by The SSP Irrevocable Trust of 2020, both for family members’ benefit, with Patel disclaiming beneficial ownership.

Does Sanjiv Patel claim beneficial ownership of the RLAY shares in the family trusts?

No. The filing states these shares are in irrevocable trusts with an independent trustee, held for his family members, and that Sanjiv Patel disclaims beneficial ownership of these securities for Section 16 and any other purpose.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 04:18 PM Accepted by SEC EDGAR 08/18/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Sanjiv

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		S(1)		48,199	D	$20.33(2)	567,699	D
Common Stock								199,548	I	By The Patel Family Irrevocable Trust of 2019(3)
Common Stock								687,355	I	By The SSP Irrevocable Trust of 2020(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

2. This transaction was executed in multiple trades at prices ranging from $19.56 to $20.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

	/s/ Soo-Yeun Lim, as attorney-in-fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)